A Phase 1 Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes

PURPOSE: Data suggest that activity of p38 MAPK and Tie2 kinase are dysregulated in MDS and may be targets for novel therapies. A Phase 1 study of ARRY-614, an oral dual inhibitor of p38 MAPK and Tie2, was conducted in patients with low or intermediate-1 International Prognostic Scoring System risk...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Garcia-Manero, Guillermo, Khoury, Hanna J., Jabbour, Elias, Lancet, Jeffrey, Winski, Shannon L., Cable, LouAnn, Rush, Selena, Maloney, Lara, Hogeland, Grant, Ptaszynski, Mieke, Calvo, Monica Cabrero, Bohanan, Zach, List, Alan, Kantarjian, Hagop, Komrokji, Rami
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4348327/
https://ncbi.nlm.nih.gov/pubmed/25480830
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1765
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados